Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of liraglutide in adults with obesity or overweight with metabolic abnormalities
CTR20201449Phase 3Active
- Sponsor
- Wanbang Biopharmaceuticals
- Start
- Aug 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of liraglutide in obesity, Overweight, sponsored by Wanbang Biopharmaceuticals. Started Aug 2020; status: active.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20201449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201449.